ENO3: A Protein Implicated in Disease Development (G2027)

Target Name: ENO3

NCBI ID: G2027

ENO3

ENO3: A Protein Implicated in Disease Development

ENO3 (ENO3 variant 1) is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and lungs. It is a key component of the endoplasmic reticulum (ER), which is the protein synthesis and quality control facility of the cell. ENO3 plays a crucial role in the ER by helping to transport and process proteins into the cell.

Research has shown that ENO3 is involved in a number of important cellular processes, including the regulation of protein synthesis, cell signaling, and inflammation. It has also been shown to play a role in the development and progression of a number of diseases, including cancer.

One potential drug target for ENO3 is the inhibition of its activity in the ER. This can be done through a variety of methods, including the use of small molecules, antibodies, or other therapeutic agents that target specific regions of ENO3. By inhibiting ENO3's activity in the ER, it is possible to reduce the production of proteins and disrupt the ER-associated signaling pathways that are involved in a number of cellular processes.

Another potential drug target for ENO3 is the targeting of ENO3 itself with antibodies or other therapeutic agents. This can be done to deliver specific molecules to the ER and target ENO3 directly, rather than targeting its activity in the ER. By doing so, it is possible to alter the activity of ENO3 and disrupt its role in the ER and other cellular processes.

ENO3 is also a potential biomarker for a number of diseases. The ER is a complex organ that is involved in the production and regulation of a wide variety of proteins, many of which are involved in disease development and progression. By studying the expression and activity of ENO3, researchers may be able to identify new biomarkers for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, ENO3 is a protein that is involved in a number of important cellular processes and has been implicated in the development and progression of a number of diseases. The inhibition of its activity in the ER or the targeting of ENO3 with antibodies or other therapeutic agents may be potential drug targets for ENO3. Further research is needed to fully understand the role of ENO3 in cellular processes and its potential as a biomarker for disease.

Protein Name: Enolase 3

Functions: Glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. Appears to have a function in striated muscle development and regeneration

The "ENO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets